Catalyst Biosciences, Inc. (CBIO)
After hours:
| Previous close | 1.5500 |
| Open | 1.5500 |
| Bid | 1.5000 x 3100 |
| Ask | 1.5300 x 1800 |
| Day's range | 1.4820 - 1.5800 |
| 52-week range | 0.3500 - 5.2000 |
| Volume | |
| Avg. volume | 6,041,030 |
| Market cap | 47.53M |
| Beta (5Y monthly) | 1.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.5480 |
| Earnings date | 03 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 20 Aug 2015 |
| 1y target est | 15.50 |
- GlobeNewswire
Catalyst Biosciences Sells Complement Portfolio for $60 Million
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash. Management Comments“We have been exploring strategic alternatives to monetize our assets and maximize value f
- GlobeNewswire
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022. “In the first quarter, we regained the rights to CB 2782-PEG, a C3 degrader protease, for the potential treatment of dry age-related macular degeneration (“AMD”) and now have full rights to two wholly-owned, potential best-in-class complement candidates that may provide compelling opportunities in o
- Simply Wall St.
Here's Why Catalyst Biosciences (NASDAQ:CBIO) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
